Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case

Cover Page

Cite item

Full Text

Abstract

The combination of lenvatinib and pembrolizumab has emerged as the first non-chemo treatment for advanced endometrial cancer, particularly in cases refractory to standard therapies. This case describes the efficacy and safety of the combination of lenvatinib and pembrolizumab in the treatment of a 62-year-old patient with endometrioid adenocarcinoma who received first-line therapy with the combination of lenvatinib and pembrolizumab in the absence of repair system deficiency after adjuvant therapy. This combination offers the potential to extend survival in patients with mismatch repair proficient endometrial cancer who have received systemic neoadjuvant or adjuvant therapy.

About the authors

E. A. Khachaturyan

Oncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare Department

Author for correspondence.
Email: dr.elinaonco@mail.ru

Elina Arturovna Khachaturyan

Build. 7, 18A Zagorodnoe Shosse, Moscow 117152

Russian Federation

T. G. Antonova

Oncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare Department

Build. 7, 18A Zagorodnoe Shosse, Moscow 117152

Russian Federation

O. A. Stativko

Oncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare Department

Build. 7, 18A Zagorodnoe Shosse, Moscow 117152

Russian Federation

I. A. Pokataev

Oncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare Department

ORCID iD: 0000-0001-9864-3837

Build. 7, 18A Zagorodnoe Shosse, Moscow 117152

Russian Federation

References

  1. Rahib L., Smith B.D., Aizenberg R. et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–21. doi: 10.1158/0008-5472.CAN-14-0155
  2. Zhang S., Gong T.T., Liu F.H. et al. Global, regional, and national burden of endometrial cancer, 1990–2017: Results from the Global Burden of Disease Study, 2017. Front Oncol 2019;9:1440. doi: 10.3389/fonc.2019.01440
  3. Lortet-Tieulent J., Ferlay J., Bray F., Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2018;110:354–61. doi: 10.1093/jnci/djx214
  4. Malignant neoplasms in Russia in 2021 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, O.A. Shakhzadova. Moscow: Moskovskiy nauchno-issledovatelskiy onkologicheskiy institut im. P.A. Gertsena – filial FGBU “Natsionalnyy meditsinskiy issledovatelskiy tsentr radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).
  5. SEER Register. Uterine Cancer – Cancer Stat Facts. Available at: https://seer.cancer.gov/statfacts/html/corp.html.
  6. Nechushkina V.M., Kolomiets L.A., Kravets O.A. et al. Practical recommendations for drug treatment of uterine body cancer and uterine sarcomas. Prakticheskie rekomendatsii RUSSCO, chast 1. Zlokachestvennye opukholi = Practical Recommendations RUSSCO, Part 1. Malignant Tumors 2023;(13):263–79. (In Russ.).
  7. Makker V., Colombo N., Casado Herráez A. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437–48. doi: 10.1056/nejmoa2108330
  8. Rumyantsev A.A. Efficient sequence of therapy for advanced and metastatic endometrial cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2022;18(2):119–26. (In Russ.). doi: 10.17650/1994-4098-2022-18-2-119-126
  9. Leon-Castillo A., De Boer S.M., Powell M.E. et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38(29):3388–97. doi: 10.1200/JCO.20.00549
  10. Marth C., Moore R.G., Bidziński M. et al. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. J Clin Oncol 2024;43(9). doi: 10.1200/JCO-24-01326
  11. Madan E., Palma A.M., Vudatha V. et al. Cell competition in carcinogenesis. Cancer Res 2022;82(24):4487–96. doi: 10.1158/0008-5472.CAN-22-2217
  12. Tyulyandina A., Kedrova A., Graft N. et al. Effectiveness and safety of lenvatinib and pembrolizumab (LenPem) therapy for endometrial cancer (EC): Results from a Russian multicenter database. Int J Gynecol Cancer 2021;31(Suppl):A123, A124. Available at: https://ijgc.bmj.com/content/31/Suppl_3/A123.3.
  13. Nechushkina V.M., Kolomiets L.A., Kravets O.A. et al. Uterine body cancer and uterine sarcomas. Prakticheskie rekomendatsii RUSSCO, chast 1.2. Zlokachestvennye opukholi = Practical Recommendations RUSSCO, Part 1.2. Malignant Tumors 2024;14(3s2):165–88. (In Russ.).
  14. Clinical guidelines “Uterine body cancer and uterine sarcomas”. Ministry of Health of Russia, 2025. (In Russ.).
  15. Makker V., Lorusso D., Moore R. et al. Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/ KEYNOTE-775. 2023 Annual Meeting on Women’s Cancer, March 25–28, Tampa, Florida. Poster of abstract #518.
  16. Prendergast E.N., Holman L.L., Liu A.Y. et al. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. Gynecol Oncol 2019;154:461–6. doi: 10.1016/j.ygyno.2019.06.016
  17. Makker V., Aghajanian C., Cohn A.L. et al. A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (study 111/KEYNOTE-146): Long-term efficacy and safety update. J Clin Oncol 2023;41(5):974–9. doi: 10.1200/JCO.22.01021

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.